Navigation Links
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
Date:2/25/2008

FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.

"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."

"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."

Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusiv
'/>"/>

SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
2. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
3. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
6. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
7. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
8. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
10. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
11. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
(Date:5/16/2013)... 2013 The Stirling Ultracold Model ... Inc., Athens, OH, USA, won the Outstanding New Product ... Society for Biological and Environmental Repositories (ISBER) at their ... one product annually, recognizes the company’s development and introduction ... The award was presented to Global Cooling’s CEO ...
(Date:5/16/2013)... 2013 A new selection of ... Cole-Parmer is designed to meet the dynamic needs ... The new Cole-Parmer® MS-3400 Centrifuges are ... lab. They ensure a powerful and complete separation ... Their standard four-place swinging buckets hold 50-mL tubes. ...
(Date:5/16/2013)... , May 16, 2013  The registration deadline has ... Financial Officers (ABFO) 2013 National Conference, the premier conference ... May 28-31 at the Hilton San Diego Bayfront. ... this year,s conference and want to make sure as ... said Brandi Roberts , Chief Financial ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... , SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ... 2009. Revenue for the third quarter of 2009 was $25,000 ... Revenue for the nine months ended September 30, 2009 was ... 30, 2008. , Dendreon,s total operating expenses for the ...
... MADRID, November 11 Cellerix, a ... today announced the successful first closing of its financing ... current,shareholders and a select group of new investors. Cellerix ... , This round was led ...
... AMSTERDAM, November 11 Amsterdam ... human gene therapy,announced today that it has successfully treated ... proprietary gene therapy. The proof of,concept studies were performed ... of Rome, La Sapienza, Italy) and demonstrated,effectiveness in the ...
Cached Biology Technology:Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6Cellerix Raises EUR27 Million in a First Closing 2AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Jersey, and City University of New York have invented ... effectively clears organisms to be viewed under microscopes. Visikol ... is one of the few high-quality clearing solutions currently ... Enforcement Administration (DEA) due to its use as a ... for viewing organisms under a microscope. Without them, microscope ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... calculated that the bite force of the great white,s ... (also known as Big Tooth) is the highest ... carnivore ever to have existed. Shark researchers from ... Department of Primary Industries Fisheries (Australia) and University of ...
... Fruit and Vegetable Consumption Is Low among Black Men ... fruits and vegetables, daily consumption of these foods among ... researchers at Columbia and Temple universities, the University of ... study of 490 American and foreign-born black men between ...
... - JDRF said today that it has recognized the work ... the pace of science in understanding the autoimmune attack that ... severe complications of this chronic and life-threatening disease. ... Dr. Jeffrey A. Bluestone, Director of the Diabetes Center at ...
Cached Biology News:Great white's mighty bite revealed 2Highlights from the August 2008 Journal of the American Dietetic Association 2JDRF announces 2008 Scholar Award recipients 2JDRF announces 2008 Scholar Award recipients 3
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
Biology Products: